Neuroprotective strategies for Parkinson’s disease: conceptual limits of animal models and clinical trials.

Wassilios Meissner, Michael P. Hill, François Tison, Christian E. Gross, Erwan Bezard
Trends in Pharmacological Sciences. 2004-05-01; 25(5): 249-253
DOI: 10.1016/j.tips.2004.03.003

PubMed
Lire sur PubMed



1. Trends Pharmacol Sci. 2004 May;25(5):249-53.

Neuroprotective strategies for Parkinson’s disease: conceptual limits of animal
models and clinical trials.

Meissner W(1), Hill MP, Tison F, Gross CE, Bezard E.

Author information:
(1)Basal Gang in Laboratoire de Neurophysiologie, CNRS UMR 5543, Université
Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder. Although
therapies that treat the symptoms of the disease have proven efficacy, strategies
that slow or stop the neurodegenerative process are currently not available.
Recently, the National Institute of Neurological Disorders and Stroke (NINDS)
conducted a systematic assessment of candidate pharmacological agents with
putative neuroprotective properties. Twelve agents have been selected as
potential candidates for upcoming clinical trials. However, the data resulting
from the use of these agents in animal models of PD using a clinically driven
design have not been published. Furthermore, the selection of interesting
candidates should be based on the soundest clinically driven preclinical
validation. This lack of published data, associated with the conceptual limits of
the current way of testing drugs in clinical trials, prompts us to argue for
further preclinical validation of the 12 candidates.

DOI: 10.1016/j.tips.2004.03.003
PMID: 15120490 [Indexed for MEDLINE]


Auteurs Bordeaux Neurocampus